Jose Ruiz

Murcia, MU 30100, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 69 publications

Novel 2-(2'-Benzothiazolyl)-benzimidazole-Based Iridium(III) Photocatalysts Exhibit Antiproliferative Effects in 2D and 3D Cancer Cells to Bypass Hypoxia-Induced Resistance.

Novel 2-(2'-Benzothiazolyl)-benzimidazole-Based Iridium(III) Photocatalysts Exhibit Antiproliferative Effects in 2D and 3D Cancer Cells to Bypass Hypoxia-Induced Resistance.

Journal: Journal of medicinal chemistry

Published: March 16, 2026

Insights into type I photoreactivity of cyclometalated iridium(III) and ruthenium(II) photosensitizers.

Insights into type I photoreactivity of cyclometalated iridium(III) and ruthenium(II) photosensitizers.

Journal: Chemical communications (Cambridge, England)

Published: October 31, 2025

Novel Heteroleptic Iridium(III) Complexes Containing COUBPY Ligands for Effective Photoinduction of Ferroptosis for Cancer Therapy.

Novel Heteroleptic Iridium(III) Complexes Containing COUBPY Ligands for Effective Photoinduction of Ferroptosis for Cancer Therapy.

Journal: JACS Au

Published: October 29, 2025

Rationally Designed Ir(III) Complex with an Exceptionally Strong Binding to Human Serum Albumin for Targeted Photodynamic Therapy.

Rationally Designed Ir(III) Complex with an Exceptionally Strong Binding to Human Serum Albumin for Targeted Photodynamic Therapy.

Journal: Journal of medicinal chemistry

Published: March 20, 2025

Photoactivatable Cyclometalated Ir(III) Compound Penetrates the Blood-Brain Barrier in 3D Spheroidal and Advanced 3D Organoid Models of Inherently Resistant and Aggressive Brain Tumors.

Photoactivatable Cyclometalated Ir(III) Compound Penetrates the Blood-Brain Barrier in 3D Spheroidal and Advanced 3D Organoid Models of Inherently Resistant and Aggressive Brain Tumors.

Journal: ACS pharmacology & translational science

Published: February 25, 2025

Breaking the deep-red light absorption barrier of iridium(III)-based photosensitizers.

Breaking the deep-red light absorption barrier of iridium(III)-based photosensitizers.

Journal: Dalton transactions (Cambridge, England : 2003)

Published: January 09, 2025

A Novel Substituted Benzo[g]quinoxaline-Based Cyclometalated Ru(II) Complex as a Biocompatible Membrane-Targeted PDT Colon Cancer Stem Cell Agent.

A Novel Substituted Benzo[g]quinoxaline-Based Cyclometalated Ru(II) Complex as a Biocompatible Membrane-Targeted PDT Colon Cancer Stem Cell Agent.

Journal: Journal of medicinal chemistry

Published: December 02, 2024

Novel Re(I) Complexes as Potential Selective Theranostic Agents in Cancer Cells and In Vivo in Caenorhabditis elegans Tumoral Strains.

Novel Re(I) Complexes as Potential Selective Theranostic Agents in Cancer Cells and In Vivo in Caenorhabditis elegans Tumoral Strains.

Journal: Journal of medicinal chemistry

Published: March 07, 2024

Photoactivatable Ruthenium Complexes Containing Minimal Straining Benzothiazolyl-1,2,3-triazole Chelators for Cancer Treatment.

Photoactivatable Ruthenium Complexes Containing Minimal Straining Benzothiazolyl-1,2,3-triazole Chelators for Cancer Treatment.

Journal: Inorganic chemistry

Published: February 22, 2024

Novel 2-(5-Arylthiophen-2-yl)-benzoazole Cyclometalated Iridium(III) dppz Complexes Exhibit Selective Phototoxicity in Cancer Cells by Lysosomal Damage and Oncosis.

Novel 2-(5-Arylthiophen-2-yl)-benzoazole Cyclometalated Iridium(III) dppz Complexes Exhibit Selective Phototoxicity in Cancer Cells by Lysosomal Damage and Oncosis.

Journal: Journal of medicinal chemistry

Published: December 23, 2023

Photoactivatable, mitochondria targeting dppz iridium(III) complex selectively interacts and damages mitochondrial DNA in cancer cells.

Photoactivatable, mitochondria targeting dppz iridium(III) complex selectively interacts and damages mitochondrial DNA in cancer cells.

Journal: Chemico-biological interactions

Published: November 17, 2023

Ir(III) Compounds Containing a Terdentate Ligand Are Potent Inhibitors of Proliferation and Effective Antimetastatic Agents in Aggressive Triple-Negative Breast Cancer Cells.

Ir(III) Compounds Containing a Terdentate Ligand Are Potent Inhibitors of Proliferation and Effective Antimetastatic Agents in Aggressive Triple-Negative Breast Cancer Cells.

Journal: Journal of medicinal chemistry

Published: July 06, 2023

Showing 1-12 of 69

Last Updated: 09/26/2026